Versican silencing improves the antitumor efficacy of endostatin by alleviating its induced inflammatory and immunosuppressive changes in the tumor microenvironment

Oncology Reports

Volumn 33, Issue 6, 2015, Pages 2981-2991

  Wang, Zi ^a,b   Li, Zhixi ^a   Wang, Yuyi ^a   Cao, Dan ^a   Wang, Xia ^a   Jiang, Ming ^a   Li, Mei ^a   Yan, Xi ^a   Li, Yan ^a   Liu, Yanyang ^a   Luo, Feng ^a  

^a SICHUAN UNIVERSITY   (China)

^b GUIZHOU PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Antiangiogenic therapy; Endostatin; Tumor microenvironment; Versican

Indexed keywords

ENDOSTATIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SHORT HAIRPIN RNA; SODIUM CHLORIDE; VERSICAN; ANGIOGENESIS INHIBITOR; SMALL INTERFERING RNA; VCAN PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; GENE SILENCING; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEWIS LUNG CARCINOMA CELL; LUNG CARCINOMA; MELANOMA; MELANOMA CELL LINE; MONOTHERAPY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, LEWIS LUNG; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MELANOMA, EXPERIMENTAL; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; ENDOSTATINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; RNA, SMALL INTERFERING; TUMOR MICROENVIRONMENT; VERSICANS;

EID: 84928911854     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3903     Document Type: Article

References (32)

1. Verheul HM, Hammers H, van Erp K, Wei Y, Sanni T, Salumbides B, Qian DZ, Yancopoulos GD and Pili R: Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 13: 4201-4208, 2007.
2. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D and Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231, 2009.
3. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, Schultz L and Mikkelsen T: Efficacy, safety and patterns of response and recurrence in patients with recurrent highgrade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91: 329-336, 2009.
4. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP and Ferrara N: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+ Gr1+ myeloid cells. Nat Biotechnol 25: 911-920, 2007.
5. Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M and Sato A: Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol 109: 122-128, 2008.
6. Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S, De Pauw E and Castronovo V: Versican overexpression in human breast cancer lesions: Known and new isoforms for stromal tumor targeting. Int J Cancer 126: 640-650, 2010.
7. Wang W, Xu GL, Jia WD, Ma JL, Li JS, Ge YS, Ren WH, Yu JH and Liu WB: Ligation of TLR2 by versican: A link between inflammation and metastasis. Arch Med Res 40: 321-323, 2009.
8. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL and Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457: 102-106, 2009.
9. Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, Sadik H, Argani P, Wagner P, Vahdat LT, et al: Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res 72: 1384-1394, 2012.
10. Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y and Guo QL: Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361: 79-84, 2007.
11. Wang HL, Ning T, Li M, Lu ZJ, Yan X, Peng Q, Lei N, Zhang H and Luo F: Effect of endostatin on preventing postoperative progression of distant metastasis in a murine lung cancer model. Tumori 97: 787-793, 2011.
12. Ning T, Yan X, Lu ZJ, Wang GP, Zhang NG, Yang JL, Jiang SS, Wu Y, Yang L, Guan YS, et al: Gene therapy with the angiogenesis inhibitor endostatin in an orthotopic lung cancer murine model. Hum Gene Ther 20: 103-111, 2009.
13. Ning T, Jiang M, Peng Q, Xi Y, Lu ZJ, Peng YL, Wang HL, Lei N, Zhang H, Lin HJ, et al: Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model. Thorac Cancer 3: 229-238, 2012.
14. Huang G and Chen L: Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin. Cancer Biother Radiopharm 24: 589-596, 2009.
15. Zhang H, Wang Z, Peng Q, Liu YY, Zhang W, Wu L, Wang X and Luo F: Tumor refractoriness to endostatin anti-angiogenesis is associated with the recruitment of CD11b+Gr1+ myeloid cells and inflammatory cytokines. Tumori 99: 723-733, 2013.
16. Li XQ, Shang BY, Wang DC, Zhang SH, Wu SY and Zhen YS: Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth. Cancer Lett 301: 212-220, 2011.
17. Ben-Neriah Y and Karin M: Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 12: 715-723, 2011.
18. Hernández D, Miquel-Serra L, Docampo MJ, Marco-Ramell A and Bassols A: Role of versican V0/V1 and CD44 in the regulation of human melanoma cell behavior. Int J Mol Med 27: 269-275, 2011.
19. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS and Yang BB: Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 18: 754-756, 2004.
20. Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol 182: 4499-4506, 2009.
21. Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174, 2009.
22. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG and Ferrara N: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 106: 6742-6747, 2009.
23. Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, Abbruzzese JL and Melisi D: Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res 17: 5822-5832, 2011.
24. Gordon S and Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964, 2005.
25. Pollard JW: Trophic macrophages in development and disease. Nat Rev Immunol 9: 259-270, 2009.
26. Sica A and Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166, 2007.
27. Martinez FO, Helming L and Gordon S: Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol 27: 451-483, 2009.
28. Mantovani A, Bottazzi B, Colotta F, Sozzani S and Ruco L: The origin and function of tumor-associated macrophages. Immunol Today 13: 265-270, 1992.
29. Mantovani A and Sica A: Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol 22: 231-237, 2010.
30. Qian BZ and Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51, 2010.
31. Sica A, Saccani A and Mantovani A: Tumor-associated macrophages: A molecular perspective. Int Immunopharmacol 2: 1045-1054, 2002.
32. Kim YJ, Jung EB, Lee MS, Seo SJ, Kim MH, Lee MW and Lee CS: Rotundarpene inhibits toll-like receptor 2 activationinduced production of inflammatory mediators in keratinocytes by suppressing the Akt and NF-κB pathways. Int Immunopharmacol 18: 325-332, 2014.